Dimerix (ASX:DXB) has confirmed that the first clinical trial site in Japan is now open for recruitment, triggering the first development milestone payment of ¥400 million (~AU$4.3 million) from FUSO Pharmaceutical Industries, the exclusive licensee of DMX-200 for FSGS in Japan.
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 Australian Biotech
Latest Video
New Stories
-
This exchange on the HTA Review was about as underwhelming as it sounds
October 9, 2025 - - Latest News -
AusBiotech unveils international conference program for Australia’s biggest week in biotech
October 9, 2025 - - Australian Biotech -
Life sciences industry calls for stronger national strategy to support trials and innovation
October 9, 2025 - - Latest News -
Officials outline ongoing measures to address ADHD medicine shortages
October 9, 2025 - - Latest News -
Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs
October 9, 2025 - - Latest News -
Australian company reports positive outcome from collaboration
October 8, 2025 - - Australian Biotech -
CUREator opens $33 million funding round with CSL and AbbVie partnership
October 8, 2025 - - Latest News